USNA insider sells 3,515 shares at $30.26 – Form 4 filing
USANA Health Sciences (USNA) Form 4: Chief Sales Officer David Mulham disclosed a direct sale of company stock.
Rhea-AI Filing Summary
USANA Health Sciences (USNA) Form 4: Chief Sales Officer David Mulham disclosed a direct sale of company stock.
- Transaction date: 30 Jul 2025
- Shares sold: 3,515 common shares
- Sale price: $30.26 per share (approx. $106 k total proceeds)
- Shares owned after sale: 9,260 (direct)
No derivative securities were reported. The filing was signed on 31 Jul 2025.
Positive
- None.
Negative
- Chief Sales Officer sold 3,515 shares, reducing personal stake by roughly 27%, which can be interpreted as a modestly negative insider signal.
Insights
TL;DR: Insider sells ~28% of holdings; mildly negative sentiment, limited fundamental impact.
The CSO’s 3,515-share sale reduces his direct stake to 9,260 shares, indicating a roughly 27% trim of his prior position. While insider selling can signal reduced confidence, the dollar value (~$106k) is modest relative to USNA’s market cap and trading volume. No accompanying 10b5-1 plan is noted, so timing appears discretionary. Investors may view the move as a minor negative, but the limited size suggests minimal effect on liquidity or control.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,515 | $30.26 | $106K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did USNA report on this Form 4?
Were any derivative securities involved in this filing?
When was the Form 4 signed and filed?
AI-generated analysis. How Rhea-AI works. Not financial advice.